文献

J-GLOBAL ID：201802271288613163   整理番号：18A0851793

明細胞腎細胞癌の進化におけるランドマーク事象のタイミング: TRACERX腎【JST・京大機械翻訳】

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal

著者 (56件)： Mitchell Thomas J. (Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK) ,  Mitchell Thomas J. (Academic Urology Group, Department of Surgery, Addenbrooke’s Hospitals NHS Foundation Trust, University of Cambridge, Hills Road, Cambridge CB2 0QQ, UK) ,  Turajlic Samra (Translational Cancer Therapeutics Laboratory, the Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK) ,  Turajlic Samra (Renal and Skin Units, The Royal Marsden National Health Service (NHS) Foundation Trust, London SW3 6JJ, UK) ,  Rowan Andrew (Translational Cancer Therapeutics Laboratory, the Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK) ,  Nicol David (Renal and Skin Units, The Royal Marsden National Health Service (NHS) Foundation Trust, London SW3 6JJ, UK) ,  Farmery James H.R. (CRUK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK) ,  O’Brien Tim (Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust, Great Maze Pond, London SE1 9RT, UK) ,  Martincorena Inigo (Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK) ,  Tarpey Patrick (Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK) ,  Angelopoulos Nicos (Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK) ,  Yates Lucy R. (Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK) ,  Yates Lucy R. (Renal and Skin Units, The Royal Marsden National Health Service (NHS) Foundation Trust, London SW3 6JJ, UK) ,  Butler Adam P. (Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK) ,  Raine Keiran (Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK) ,  Stewart Grant D. (Academic Urology Group, Department of Surgery, Addenbrooke’s Hospitals NHS Foundation Trust, University of Cambridge, Hills Road, Cambridge CB2 0QQ, UK) ,  Challacombe Ben (Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust, Great Maze Pond, London SE1 9RT, UK) ,  Fernando Archana (Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust, Great Maze Pond, London SE1 9RT, UK) ,  Lopez Jose I. (Department of Pathology, Cruces University Hospital, Biocruces Institute, University of the Basque Country (UPV/EHU), Barakaldo, Spain) ,  Hazell Steve (Translational Cancer Therapeutics Laboratory, the Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK) ,  Chandra Ashish (Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust, Great Maze Pond, London SE1 9RT, UK) ,  Chowdhury Simon (Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust, Great Maze Pond, London SE1 9RT, UK) ,  Rudman Sarah (Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust, Great Maze Pond, London SE1 9RT, UK) ,  Soultati Aspasia (Guy’s and St Thomas’ National Health Service (NHS) Foundation Trust, Great Maze Pond, London SE1 9RT, UK) ,  Stamp Gordon (Experimental Histopathology Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK) ,  Fotiadis Nicos (Interventional Radiology Department, The Royal Marsden National Health Service (NHS) Foundation Trust, London SW3 6JJ, UK) ,  Pickering Lisa (Renal and Skin Units, The Royal Marsden National Health Service (NHS) Foundation Trust, London SW3 6JJ, UK) ,  Au Lewis (Renal and Skin Units, The Royal Marsden National Health Service (NHS) Foundation Trust, London SW3 6JJ, UK) ,  Spain Lavinia (Renal and Skin Units, The Royal Marsden National Health Service (NHS) Foundation Trust, London SW3 6JJ, UK) ,  Lynch Joanna (Renal and Skin Units, The Royal Marsden National Health Service (NHS) Foundation Trust, London SW3 6JJ, UK) ,  Stares Mark (Renal and Skin Units, The Royal Marsden National Health Service (NHS) Foundation Trust, London SW3 6JJ, UK) ,  Teague Jon (Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK) ,  Maura Francesco (Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK) ,  Wedge David C. (Big Data Institute, University of Oxford, Old Road Campus, Oxford OX3 7FZ, UK) ,  Horswell Stuart (Bioinformatics and Biostatistics STP, Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK) ,  Chambers Tim (Translational Cancer Therapeutics Laboratory, the Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK) ,  Litchfield Kevin (Translational Cancer Therapeutics Laboratory, the Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK) ,  Xu Hang (Translational Cancer Therapeutics Laboratory, the Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK) ,  Stewart Aengus (Bioinformatics and Biostatistics STP, Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK) ,  Elaidi Reza (Hopital Europeen Georges Pompidou 20, rue Leblanc, 75908 Paris, France) ,  Oudard Stephane (Hopital Europeen Georges Pompidou 20, rue Leblanc, 75908 Paris, France) ,  McGranahan Nicholas (Translational Cancer Therapeutics Laboratory, the Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK) ,  McGranahan Nicholas (Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6BT, UK) ,  Csabai Istvan (Department of Physics of Complex Systems, Eotvos Lorand University, Budapest, Hungary) ,  Gore Martin (Renal and Skin Units, The Royal Marsden National Health Service (NHS) Foundation Trust, London SW3 6JJ, UK) ,  Futreal P. Andrew (The University of Texas MD Anderson Cancer Center, Department of Genomic Medicine, Houston, TX 77030, USA) ,  Larkin James (Renal and Skin Units, The Royal Marsden National Health Service (NHS) Foundation Trust, London SW3 6JJ, UK) ,  Lynch Andy G. (CRUK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK) ,  Lynch Andy G. (School of Medicine, University of St. Andrews, North Haugh, St. Andrews KY16 9TF, UK) ,  Szallasi Zoltan (Centre for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark) ,  Szallasi Zoltan (Children’s Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology (CHIP@HST), Harvard Medical School, Boston, MA, USA) ,  Swanton Charles (Translational Cancer Therapeutics Laboratory, the Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK) ,  Swanton Charles (Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6BT, UK) ,  Swanton Charles (Department of Medical Oncology, University College London Hospitals, 235 Euston Rd, Fitzrovia, London NW1 2BU, UK) ,  Campbell Peter J. (Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK) ,  Campbell Peter J. (Department of Haematology, University of Cambridge, Cambridge CB2 2XY, UK)
資料名： Cell (Cambridge, Mass.)  (Cell (Cambridge, Mass.))
巻： 173  号： 3  ページ： 611-623.e17  発行年： 2018年 
JST資料番号： A0707B  ISSN： 0092-8674  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： 明細胞腎細胞癌(ccRCC)は染色体3の短腕のほぼ普遍的な消失により特徴付けられ,いくつかの腫瘍抑制遺伝子を削除する。著者らは,明らかな細胞腎細胞癌を有する33人の患者を通して,95の生検から全ゲノムを分析した。テロメア延長に関連するMYC-MAX-MAD1レプレッサーを標的とする,TERTの5′UTRにおける点突然変異のホットスポットを見出した。最も一般的な構造異常は,典型的には色素沈着を通して,同時3p損失と5q利得(36%の患者)を発生させる。このイベントは小児期または青年期に起こり,一般的に腫瘍の最も最近の一般的祖先の出現に先行する開始イベントとして数年から数十年にわたって起こっている。同様のゲノム変化は遺伝ccRCCを駆動する。遺伝性および散発性癌の間の年齢発生率のモデリングの違いは,散発性腫瘍を開始することができる3p損失を有する細胞の数が数百未満であることを示唆する。ccRCCの初期発生は明確な進化軌跡に従い,早期介入の機会を提供する。Copyright 2018 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： レプレッサー ,  生検 ,  *腎細胞癌 ,  腫瘍 ,  ホットスポット ,  点突然変異 ,  癌抑制遺伝子 ,  遺伝 ,  テロメラーゼ ,  モデリング ,  患者 ,  色素沈着 ,  ゲノム
準シソーラス用語： 染色体3 ,  *明細胞 , 【Automatic Indexing@JST】

著者キーワード (3件)： 明細胞腎細胞癌 ,  癌の進化 ,  色素沈着症

分類 (1件)： 細胞生理一般  (EF02010S)

タイトルに関連する用語 (6件)： 明細胞 ,  腎細胞癌 ,  進化 ,  ランドマーク ,  事象 ,  腎